[STUDY_ID_REMOVED]  
 
Study ID: UBR‐MD‐01 
 
Title:  A Phase 3, Multicenter,  Randomized,  Double‐Blind, Placebo‐Controlled  Single Attack Study to 
Evaluate the Efficacy, Safety,  and Tolerability  of Oral Ubrogepant  in the Acute Treatment  of Migraine 
 
Protocol Amendment  3 Date: 19 May 2017 
 
 
 
Allergan Confidential Protocol UBR -MD-01 Amendment 3
1Title Page
ALLERGAN – CONFIDENTIAL
The following contains confidential, proprietary  information 
which is the propert y of Allergan
A PHASE 3, MUL TICENTER, RANDOMIZED, DOUBLE -BLIND, PLACEBO -
CONTROLLED SINGLE ATTACK STUDY  TO EVALUA TE THE EFFICACY , 
SAFETY , AND TOLERABILITY  OF ORAL  UBROGEP ANT 
IN THE ACUTE TREA TMENT  OF M IGRAINE
Protocol Number:  UBR -MD-01Amendment 3
Phase: 3
Name of Investigational Product: Ubrogepant
Sponsor: Allergan Pharmaceuticals 
International Limited
Clonshaugh Industrial Es tate
Coolock
Dublin 17
IrelandAuthorized US Agent
Allergan Sales, LLC
2525 Dupont Drive
Irvine, California USA   92612
Emergency Telephone Number(s): Refer to the Study Contacts Sheet
Serious Adverse Event 
Reporting Fax Number:
Allergan Medical Monitor
Contact Information:Please see Study Contact sSheet
Allergan Signatory:
Original Protocol Date: 29 Apr 2016
Protocol Amendment 1 Date : 09 Jun 2016
Protocol Amendment 2 Date : 04 Nov 2016
Protocol Amendment 3 Date: 19May 2017
13AUG2018 CSR UBR-MD-01
1

Allergan Confidential Protocol UBR -MD-01 Amendment 3
2The following information can be found on FDA  Form 1572 and/or study  contacts page:  
Emergency T elephone Numbers; name, address, and statement of qualifications of each 
investigator; name of each subinvestigator working under the supervision of the investigator; 
name and address of the research fa cilities to be used; name and address of each reviewing 
IRB; US 21 CFR 312.23 section 6(iii)b.
13AUG2018 CSR UBR-MD-01
2
Allergan Confidential Protocol UBR -MD-01 Amendment 3
3Investigator Signature Page
INVESTIGATOR:
I agree to:
Implement and conduct this study diligentl y and in strict compliance with the protocol, 
good clinical practices and all applicable laws and regulations.
Maintain all information supplied by  Allergan in confidence and, when this 
information is submitted to an Institutional Review Board (IRB), Independent Ethics 
Committee (I EC) or another group, it will be submitted with a designation that the 
material is confidential.
Ensure that all persons assisting with the trial are adequatel y informed about the 
protocol, the investigational product(s), and their trial- related duties and functions.
I have read this protocol in its entirety  and I agree to all aspects.
Investigator Printed Name Signature Date
13AUG2018 CSR UBR-MD-01
3
Allergan Confidential Protocol UBR -MD-01 Amendment 3
4Table of Contents
Title Page .................................................................................................................................. 1
Investigator Signature Page ...................................................................................................... 3
Table of Contents ...................................................................................................................... 4
List of T ables ............................................................................................................................. 7
List of Figures -..........................................................................................................................
7
Protocol Summary .................................................................................................................... 8
1. Background and Clinical Rationale ............................................................................ 15
2. Study  Objectives and Clinical Hy potheses ................................ ................................ . 17
2.1 Study  Objectives ............................................................................................. 17
2.2 Clinical Hy potheses ........................................................................................ 17
3. Study  Design ............................................................................................................... 17
3.1 Adjudica tion Committee and Data Safet y Monitoring Board ........................ 18
4. Study  Population and Entry  Criteria ........................................................................... 19
4.1 Number of Patients ................................
......................................................... 19
4.2 Study  Population Characteristics .................................................................... 19
4.3 Inclusion Criteria ............................................................................................ 19
4.4 Exclusion Criteria ................................
........................................................... 20
4.5 Permissible and Prohibited Medications/Treatments...................................... 23
4.5.1 Permissible Medications/Treatments ..................................................
23
4.5.1.1 Acute Treatment /Rescue Medication .................................. 24
4.5.1.2 Definition of Females of (Non -)Childbearing Potential 
and/or Acceptable Contraceptive Methods .......................... 24
4.5.2 Prohibited Medications/Treatments .................................................... 25
4.5.3 Special Diet or Activities ....................................................................
26
5. Study  Treatments ........................................................................................................ 26
5.1 Study  Treatments and Formulations ............................................................... 26
5.2 Control Treatment ................................ ................................ ........................... 26
5.3 Methods for Masking/Blinding ....................................................................... 26
5.4 Treatment Allocation Ratio and n................................ ................ 26
5.5 Method for Assignment to Treatment 
Groups/Randomization ............................................................. 27
5.6 Treatment Regimen and Dosing ................................ ................................ ..... 28
5.6.1 Treatment Administration ................................ ................................ ... 28
5.6.3 Optional Second Dose and Rescue Medication ................................ .. 29
13AUG2018 CSR UBR-MD-01
4

Allergan Confidential Protocol UBR -MD-01 Amendment 3
55.7 Storage of Investigational Products/Treatments ............................................. 30
6. Response Measures and Summary of Data Collection Methods ................................ 30
6.1 Efficacy  Measures ...........................................................................................
30
6.6 Other Study  Supplies ...................................................................................... 37
6.7 Summary  of Methods of Data Collection ....................................................... 38
7. Statistical Procedures .................................................................................................. 38
7.1 Analy sis Populations ....................................................................................... 38
7.1.1 Modified Intent -to-treat Population ................................ .................... 38
7.1.2 Safety  Population ................................................................................ 38
7.2 Collection and Derivation of Efficacy  Assessments ....................................... 38
7.2.1 Primary  Efficacy  Variables ................................................................. 38
7.2.2 Secondary  Efficacy  Variables ............................................................. 39
7.3 Hypothesis and Methods of An alysis............................................................. 41
7.3.1 Efficacy  Anal yses............................................................................... 41
7.3.1.1 Primary  Efficacy  Anal yses.................................................. 41
7.3.1.2 Secondary  Efficacy  Analy ses.............................................. 42
7.3.2 Pharmacokinetic Analy ses.................................................................. 44
7.6 Interim Anal yses................................ ................................ ............................. 51
13AUG2018 CSR UBR-MD-01
5

Allergan Confidential Protocol UBR -MD-01 Amendment 3
68. Patient Entry  Procedures ................................ ................................ ............................. 51
8.1.1 Overview of Entry  Procedures ............................................................ 51
8.1.2 Informed Consent and Patient Privacy ............................................... 51
8.2 Washout I ntervals/Run -In............................................................................... 52
8.5 Instructions for the Patients ............................................................................ 58
8.6 Unscheduled Visits ......................................................................................... 59
8.7 Compliance with Protocol............................................................................... 59
8.8 Early Discontinuation of Patients ................................
................................... 59
8.9 Withdrawal Criteria ........................................................................................
60
8.11 Study  Termination ................................ ................................ .......................... 60
9. Adverse Events ........................................................................................................... 61
9.1 Defini tions....................................................................................................... 61
9.1.1 Adverse Event ..................................................................................... 61
9.1.2 Serious Adverse Event ................................
........................................ 61
9.1.3 Severity ............................................................................................... 62
9.1.4 Relationship to Study  Drug or Stud y Procedure ................................. 62
9.2 Procedures for Reporting Adverse Events ...................................................... 62
9.3 Procedures for Reporting a Serious Adverse Event ........................................
63
9.4 Exposure to I nvestigational Product during Pregnancy .................................. 63
9.7 Procedures for Unmasking of Investigational Product ................................ ... 66
10. Administrative I tems ................................................................................................... 66
10.1 Protection of Human Patients ......................................................................... 66
10.1.1 Compliance With I nformed Consent Regulations (US 21 CFR Part 
50) and Relevant Country  Regulations ................................ ............... 66
10.1.2 Compliance With I RB or I EC Regulations ................................ ......... 66
10.1.3Compliance With Good Clinical Practice ................................ ........... 67
10.1.4 Compliance With Electronic Records; Electronic Signatures 
Regulations (US 21 CFR Part 11) ....................................................... 67
10.2 Changes to the Protocol ................................ ................................ .................. 67
10.3 Patient Confidentiality ................................ ................................ .................... 67
10.3.1 Patient Privacy ................................ ................................ .................... 67
10.4 Documentation ................................ ................................ ................................ 68
10.4.1 Source Documents ................................ ................................ .............. 68
10.4.2 Electronic Case Report Form Completion ................................ .......... 69
13AUG2018 CSR UBR-MD-01
6

Allergan Confidential Protocol UBR -MD-01 Amendment 3
710.4.3 Study  Summary ................................................................................... 69
10.4.4 Retention of Documentation ............................................................... 69
10.5 Labeling, Packaging, and Return or Disposal of Investigational 
Products/Treatments ....................................................................................... 70
10.5.1 Labeling/Packaging ............................................................................. 70
10.5.2 Clinical Supply  Inventory ................................................................... 70
10.5.3 Return or Disposal of Investigational Products/Treatments and/or 
Supplies ............................................................................................... 70
10.6 Monitoring b y the Sponsor ................................
............................................. 70
10.7 Handling of Biological Specimens/Samples................................................... 71
10.8 Publications ................................
..................................................................... 71
10.9 Coordinating Investigator ...............................................................................
71
11. References ................................................................................................................... 72
12. Attachments ................................................................................................................ 74
12.1 Examination Procedures, Tests, Equipment, and Techniques ........................ 74
12.1.1 International Classification of Headache Disorders, 3rdEdition, 
Beta Version ........................................................................................
74
12.2 Examples of Prohibited Medications .............................................................. 89
12.3 Glossary  of Abbreviations .............................................................................. 92
12.4 Protocol Amendment 1 Summary ................................................................... 94
12.5 Protocol Amendment 2 Summary ................................................................... 97
12.6 Protocol Amendment 3 Summary ................................................................. 103
List of Tables
Table 2 Treatments Administered for Initial and Optional Second Dose.................... 28
Table 3 Clinical L aboratory  Parameters ......................................................................
35
Table 4 Assumed Response Rates and Estimated Power for Primary  and Secondary  
Efficacy  Endpoints .......................................................................................... 51
List of Figur es
13AUG2018 CSR UBR-MD-01
7

Allergan Confidential Protocol UBR -MD-01 Amendment 3
8Protocol Summary
Study Compound(s):  Ubrogepant
Phase:  3
Study Objective:  To evaluate the efficacy, safety , and tolerability of 2 doses of ubrogepant (50mg and 
100mg) compared to placebo for the acute treatment of a single migraine attack
Clinical Hypotheses:
1.  At least 1ubrogepant dose is superior to placebo in the acute treatment o f migraine .
2.  Ubrogepant is safe and tolerable.
StudyDesign
Structure:  Multicenter, randomized, double- blind ,placebo -controlled , parallel -group, single attack study;
randomization to placebo, ubrogepant 50 m g, or ubrogepant 100 m g.
Duration :  The study includes a screening period of up to 14 days prior to randomization, a 60 -day period in 
which to treat a single migraine attack, and a 4 -week follow -up period.
Study Treatment Groups :  Ubrogepant 50 mg, ubrogepant 100 mg
Controls :  Ubrogepant p lacebo
Dosage/Dose Regimen :  Study participants will have up to 6 0 days to treat a single qualifying migraine attack of 
moderate or severe headache pain intensity at home. Patients have the option to take a second dose of 
investigational product (IP)or rescue medication if the patient has either a nonresponding migraine or a 
migraine recurrence.  
  
 
 
 
 
 
 
Study Population Characteristics
Number of Patients :  Approximately 1650 patients will be randomized (550per treatment arm)
Condition/Disease :  Migraine with or without aura
Key Inclusion Criteria :  To be eligible for study participation, patients must be 18 to 75 years of age (inclusive) , 
have a history of migraine with or w ithout aura for at least 1 year consistent with a diagnosis according to the
International Classification of Headache Disorders criteria , 3rdedition, beta version ( ICHD -3 beta, 2013 ) and 
experience between 2 to 8 migraine attacks with moderate to severe headache pain in each of the 3 months prior 
toScreening (Visit 1) .
Key Exclusion Criteria :  
13AUG2018 CSR UBR-MD-01
8

Allergan Confidential Protocol UBR -MD-01 Amendment 3
9Response Measures
Efficacy :  Rating of headache severity, absence or presence of migraine -associated symptoms, use of rescue 
medication, use of optional second dose, and recurrence of headache pain
 
 
General Statistical Methods and Types of Analyses:   The efficacy analyses will be based o n the Modified 
Intent -to-treat ( mITT )Population. The last observation carried forw ard (LOCF) approach will be used to impute 
missing posttreatment values. Baseline for efficacy is defined as the last nonmissing efficacy assessment before 
the initial dose of study treatment. For each primary variable, the observed response proportion s will be 
provided by treatment group. Theprimary efficacy variable of pain freedom at 2 hours after the initial dose will 
be analyzed using a logistic regression model with categorical terms for treatment group, historical triptan 
response (triptan responder, triptan insufficient responder, or triptan naïve), use of medication for migraine 
prevention (yes/no), and baseline headache severity (moderate or severe). The primary efficacy variable of 
absence of the most bothersome symptom at 2 hours after the i nitial dose will be analyzed using a similar 
logistic regression model with an additional categorical term for the underlying symptom that was identified as 
the most bothersome. The respective comparisons of the ubrogepant dose sversus placebo, which are t he formal 
tests of the efficacy hypotheses, w ill be conducted using the appropriate pairw ise contrasts within the logistic 
regression model. For secondary and other efficacy endpoints related to migraine headache pain severity and/or 
recurrence, migraine -associated symptoms, or use of rescue medication (including the second dose of IP), the 
observed response proportions w ill be analyzed using the same methods used to analyze the primary efficacy 
variables. For secondary efficacy endpoints on migraine -associ ated symptoms, baseline presence/absence of the 
symptom will be included as an additional covariate for the logistic regression model .The proportion of 
patients reporting satisfaction with study medication at 2 and 24 hours after the initial dose, the pro portion of 
patients able to function normally at 1, 2, 4, and 8 hours after the initial dose, and the proportion of patients 
assessed by the PGIC as “much better ” or “very much better” at 2 hours after the initial dose will be analyzed 
using the same methods used to analyze the primary efficacy variables. The baseline functional disability score 
will also be included as a covariate for the analysis of the proportion of patie nts able to function normally. For 
the change from baseline in EQ-5D-5Lindex value at 24hours 
after the initial dose, treatment comparisons of 
ubrogepant dose groups versus placebo will be performed using an analysis of covariance (ANCOVA) model 
with cat egorical terms for treatment group, baseline severity, historical triptan response, and use of medication 
for migraine prevention, and with the baseline EQ-5D-5L index value as a covariate. Descriptive statistics will 
be provided for the change from baseli ne in the EQ VAS score at 24 hours after the initial dose by treatment 
group.
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
9

Allergan Confidential Protocol UBR -MD-01 Amendment 3
10 
 
13AUG2018 CSR UBR-MD-01
10

Allergan Confidential Protocol UBR -MD-01 Amendment 3
11Figure1 Study Flow Diagram
13AUG2018 CSR UBR-MD-01
11

Allergan Confidential Protocol UBR -MD-01 Amendment 3
13AUG2018 CSR UBR-MD-01
12

Allergan Confidential Protocol UBR -MD-01 Amendment 3
13
13AUG2018 CSR UBR-MD-01
13

Allergan Confidential Protocol UBR -MD-01 Amendment 3
14
13AUG2018 CSR UBR-MD-01
14

Allergan Confidential Protocol UBR -MD-01 Amendment 3
151. Background and Clinical Rationale
What is Migraine and How Prevalent is It?
Migraine affects 18% of women and 6% of men in the United States with a peak prevalence 
occurring between the ages of 25 to 55 years. Approximately  one-third of migraineurs have 
3 or more migraine headaches per month, and over half report severe impairment or the need 
for bed rest during a n attack ( Lipton et al, 2007). In the U nited States, work loss due to 
migraine is estimated to cost ~ $13 billion annually ( Hu et al, 1999
). Prevalence is similar in 
Europe, with migraine headache affecting 17.6% of women and 8% of men 
(Stovner andAndree, 2010
).It is currently  ranked by  the W orld Health Organization as 19th 
among causes of disability  (Katsarava et al, 2012). 
Migraine is ty pically  characterized by  attacks of throbbing, unilateral headache of moderate 
or severe pain intensity , associated with nausea, vomiting, and/or sensitivity to light 
(photophobia) and sound (phonophobia). In about 25% of individuals, migrain e headache 
may be preceded b y focal neurological dy sfunction (aura). Improving the diagnosis and 
optimizing treatments for migraine have been recognized as critically  important to reduce the 
global burden of 
migraine ( Katsara va et al, 2012
).
Because there are no biological markers for migraine, diagnosis is based on clinical history , 
exam, and the exclusion of other headache disorders. Phy sicians appl y clinical criteria to 
guide diagnoses and subsequent treatment. Episodic mig raine is a s yndrome diagnosis 
applied to patients with migraine (with or without aura) who have 1 to 14 headache day s per 
month. Chronic migraine is a specific International Classification of Headache Disorders 
criteria, 3rdedition beta version (ICHD -3 be ta)diagnosis applied to a subset of patients with 
≥15 headache day s per month ( ICHD-3 beta , 2013; Katsarava et al, 2012 ; 
Olesen etal,2006). 
What is CGRP  and What is itsRelationship to Migraine ?
CGR P(calcitonin gene-related peptide) isaneuropeptide implicated in thepathoph ysiology 
ofmigraine. CGR Plevels inthe cranial venous outflow (ie, external jugular vein) are
increased durin g amigraine attack ( Goadsb yand Edvinsson , 1993
) and exogenous ly
administered CGR Phasbeen shown to trigger migraine- likeheadache in migraineurs. The 
majorit y
(80%to 90%) oftrigeminal Aδfibers thatinnervate thedura contain CGRP ,
suggesting that these fibers may be involved insterile neurogenic inflammation and
migraine pain transmission. Furthermore, the CGRP receptor is present on human meningeal
andcerebral blood vessels. These observations suggest that activation of the 
13AUG2018 CSR UBR-MD-01
15
Allergan Confidential Protocol UBR -MD-01 Amendment 3
16trigeminovascular s ystem, with release of CGRP , may play  a key  role in migraine 
pathogenesis and that inhibition of CGRP function may yield anovel therapeutic approach to
treating migraine.
Establishment of CGRP  Antagonism to Treat Migraine
The abilit y of CGR Pantagonism torelieve pain inthe acute treatment of migraine was
established byusing anintravenous (I V)formulation ofolcegepant (Olesen etal,2004), 
andreplicated by Merck & Co.,Incwith anoral formulation oftelcagepant, ahighly
selective CGR Preceptor antagonist (CGRP RA). InPhase 3studie s,telcagepant was
superior to placebo inthe primary  endpoints of 2
-hour pain freedom, 2- hour pain relief, 
and the absence of associated symptom s(photophobia, phonophobia, andnausea), aswell as
thekey secondar y endpoint of 24-hour sustained pain freedom (Connor et al, 2009 ). 
Serum alanine aminotransferase (AL T) increases were observed with telcagepant as well as 
with a second CGRP  antagonist, MK- 3207. For this reason, the development of these 
compounds was stopped. 
What is U brogepant?
Ubrogepant, a novel CGRP  receptor antagonist that is chemicall y distinct from both 
telcagepant and MK -3207, is now bei ng developed for the acute treatment of migraine. 
Preclinical and clinical studies conducted to date for ubrogepant have shown no evidence of 
hepatoto xicity .
A Phase 2b clinical study was conducted, which compared 1-, 10-
, 25-, 50- , and 100- mg 
doses of ubr ogepant to placebo in the acute treatment of migraine. Overall, all the ubrogepant 
doses tested were well tolerated and t he adverse event (AE) profile of all ubrogepant doses 
did not dif fer significantly  from placebo. For the primary  efficacy  endpoint of pain freedom
at 2hours, ubrogepant doses of 1 and 10 mg did not dif fer from placebo, but doses of 25, 50, 
and 100 mg were better than placebo. For the primary  efficacy  endpoint of pain relief at 
2hours none of the ubrogepant doses dif fered from placebo , p
robabl y due to a high placebo 
response rate .
The a bsence of migraine -associated s ymptoms of photophobia, phonophobia, and nausea was
assessed as key  secondary  endpoints. Ubrogepant doses of 50 and 100 mg were significantly  
better than placebo for absence o f phonophobia and photophobia at 2 hours, whereas 25 mg 
did not dif fer from placebo. None of the ubrogepant doses dif fered from placebo for the 
endpoint of absence of nausea at 2 hours. Measures of sustained migraine headache relief 
13AUG2018 CSR UBR-MD-01
16
Allergan Confidential Protocol UBR -MD-01 Amendment 3
17(2to 24 hours and 2 to 48 hours sustained pain freedom and sustained pain relief) generally  
suggest edthat ubrogepant 50 mg and 100 mg were more effective than the 25 -mg dose.
The purpose of this study will be to assess the safety and ef ficacy  of 2 doses of ubrogepant, 
50 and 100 mg, versus placebo in the acute treatment of migraine with or without aura, in a 
randomized, double -blind, placebo -controlled Phase 3 study .
2. Study Objectives and Clinical Hypotheses
2.1 Study Objectives
To evaluate the efficacy , safety , and tolerability of 2 doses of ubrogepant (50 and 100 mg) 
compared to placebo for the acute treatment of a single migraine attack.
2.2 Clinical Hypotheses
1.At least 1ubrogepant dose is superior to placebo in the acute treatment of migraine .
2.Ubrogepant is safe and tolerable.
3. Study Design
This multicenter , randomized, double -blind, placebo -controlled, parallel -group, single attack
study  will enroll approximately  1650 patients from approximately  100 centers in the United 
States. Patients will be randomized (1:1:1) to 1 of the fol lowing 3 treatment groups: placebo, 
ubrogepant 50 mg, or ubrogepant 100 mg.
Study  participants will have up to 60 day sto treat a single qualify ing migraine attack of 
moderate or severe intensity  at home. Patients unable to treat a qualify ing migraine with in 
this time will be discontinued from the study .
 
 
 
 
 
 
The p lanned ef ficacy  assessments are rating of headache severity , absence or presence of 
migraine -associated s ymptoms, use of rescue medication, use of optional second dose ,and 
13AUG2018 CSR UBR-MD-01
17

Allergan Confidential Protocol UBR -MD-01 Amendment 3
18recurrence of headache pain. A list and description of each efficacy  assessment is in 
Section 6.1 and the efficacy anal yses are presented in Section 7.3.1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1 Adjudication Committee and Data Safety Monitoring Board
An Adjudication Charter will be established and will describe the process for the blinded 
surveillance, monitoring, and adjud ication b y the Clinical Adjudication Committee of events 
of posttreatment elevations of ALT and/or aspartate aminotransferase ( AST ) ≥3 times the 
upper limit of normal (ULN) in the ubrogepant program. The purpose of this committee 
charter will be to provid e a standardized process for the adjudication of data associated with 
these events in order to determine whether the elevation was related to ubrogepant.
13AUG2018 CSR UBR-MD-01
18

Allergan Confidential Protocol UBR -MD-01 Amendment 3
19An independent Data Safety  Monitoring Board (DSMB) will also be established to review 
unblinded safet y data and summary reports, identify  any safety issues and trends ,and make 
recommendations to the Sponsor , including modification or early  termination of a trial, if 
emerging data show unexpected and clinically significant adverse events of treatment.
Details of the DSMB memberships, standard operational procedures for data 
monitoring/review , frequency  of review , and other pertinent details will be provided in a 
separate DSMB Charter .
4. Study Population and Entry Criteria
4.1 Number of Patients
Approximately  1650 patients will be randomized ( 550patients per arm) from approximately  
100 centers in the United States.
4.2 Study Population Characteristics
This study  will include adult patients with migraine with or without aura.
4.3 Inclusion Criteria
To be eligible to pa rticipate in the study , patients must meet the following criteria:
1.Written informed consent and patient privacy  information (eg, Written Authorization 
for Use and Release of Health and Research Stud y Information) obtained from the 
patient prior to initiati on of an y study -specific procedures
2.Male or female patients ages 18 to 75 years, inclusive, at Visit 1
3. At least a
1-year history  of migraine with or without aura consistent with a diagnosis 
according to the International Classification of Headache Disorder s
, 3rdedition, beta 
version ( ICHD -3beta, 2013; Section 12.1.1)
4.Migraine onset before age 50
5.By history , the patient’ s migraines typically  last between 4 and 72 hours if untreated or 
treated unsuccessfull y and migraine episodes are separated b y at least 48 hours of 
headache pain freedom
6.History  of 2 to 8 migraine att acks per month with moderate to severe headache pain in 
each of the 3 months prior to Screening ( Visit 1)
 
.
13AUG2018 CSR UBR-MD-01
19

Allergan Confidential Protocol UBR -MD-01 Amendment 3
208.Be abl e to read, understand and complete the study  questionnaires and eDiary .
4.4 Exclusion Criteria
Patients who meet an y of the following criteria will not be eligible to participate in the study:
 
 
2. Dif ficult y distinguishing migraine headache from tension -type or other headaches. 
 
 
 
 
 
 
4.Has taken medication for acute treatment of headache (including acetaminophen, 
nonsteroidal anti- inflammatory  drugs [ NSAI Ds], triptans, ergotamine, opioids, or 
combination analgesics) on 10 or more day s per month in any  of the 3months prior to 
Visit 1. 
5.Has a history  of migraine aura with diplopia or impairment of level of consciousness , 
hemiplegic migraine, or retinal migrai ne as defined by  ICHD -3 beta (Section 12.1.1
)
6.Has a current diagnosis of new persistent daily  headache, trigeminal autonomic 
cephalgia (eg, cluster headache), or pa inful cranial neuropath yas defined by  
ICHD -3beta ( Section 12.1.1)
7. Required hospital treatment of a migraine attack 3 or more times in the 6 month sprior 
to Visit 1
.
 
 
 
13AUG2018 CSR UBR-MD-01
20

Allergan Confidential Protocol UBR -MD-01 Amendment 3
21 
 
9.Has a chronic non -headache pain condition requiring dail y pain medicati on(with the 
exception of pregabalin)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
21

Allergan Confidential Protocol UBR -MD-01 Amendment 3
22 
 
 
 
 
 
 
 
20.History  of malignancy  in the 5 y ears prior to Visit 1, except for adeq uatel y treated 
basal cell or squamous cell skin can cer, or in situ cervical cancer
21.History  of any prior gastrointestinal (GI) conditions (eg, diarrhea s yndromes, 
inflammatory  bowel disease) that may  affect the absorption or metabolism of 
investigational pr oduct (IP); patients with prior gastric bariatric interventions (eg, Lap 
Band )which have been reversed are not excluded
22.History  of acute hepatitis within 6 months ofScreening (Visit1) or chronic hepatitis 
(including nonalcoholic steatohe patitis) or apositive resulton anti -hepatitis A 
immunoglobulin M ( IgM)antibody ,hepatitis Bsurface antigen, or anti –hepatitis C
antibodytesting at Screening (V isit 1)
 
 
 
 
13AUG2018 CSR UBR-MD-01
22

Allergan Confidential Protocol UBR -MD-01 Amendment 3
23 
 
 
4.5 Permissible and Prohibited Medications/T reatments
4.5.1 Permissible Medications/T reatments
Medications which are not specificall y prohibited are allowed ; however, there may  be
clarifications and restrictions with certain medications.
The following medications are allowed during the study , but are prohibited within 48 hours 
prior to taking IP:
any triptan
any ergot derivative
any opioid
any NSAID
any other form of analgesic (including acetaminophen)
any antiemetic agent
any proton pump inhibitor
The following medications are allowed during the study , but are 
prohibited within 24 hours 
prior to taking IP:
any antacid
any H2blocker
Examples of allowed but restricted medications listed above are display ed in 
Attachment 12.2.
Aspirin up to 325 mg/day  is allowed for cardiac prophy laxis.
Daily  use of pregabalin is allowe d. 
13AUG2018 CSR UBR-MD-01
23

Allergan Confidential Protocol UBR -MD-01 Amendment 3
24Selective serotonin reuptake inhibitors (SSRI ) or serotonin norepinephrine reuptake 
inhibitors (SNRI ) will be permitted provided that treatment is stable for at least 60 day s prior 
to screening (Visit 1) and continues without change in dose throughout the study . SSRI s and 
SNRI s may  not be started during the study .
Standard migra ine prophy lactic medications (e g, beta -blocker, tricy clic antidepressant, 
topiramate, valproic acid, botulinum toxin) will be permitted provided that the treatment is 
stable for at least 30 day s prior to Visit 1, and continues without change in dose throughout 
the study . Prophy lactic medications may  not be started during the study .
Therap y considered necessary  for the patien t's welfare may  be given at the di scretion of the 
investi gator . If the permissibility  of a specific medication/treatment is in question, please 
contact Allergan.
4.5.1.1 AcuteTreatment / Rescue Medication
Medications for acute treatment of migraine listed above may  be taken during the study  
within the parameters noted in Section 4.5.1.  
 
 
 
For details regarding the requirements for 
treatment with rescue medication and optional second dose, please refer to S ection 5.6.3.
 
 
 
 
4.5.1.2 Definition of Females of (Non-)Childbearing Potential and/or 
Acceptable Contraceptive Methods
For purposes of this study , females will be considered of childbearing potential unless they  
are naturall y postmenopausal 
(ie, no menses for 2 y ears) or permanently  sterilized 
(ie,bilateral tubal liga tion, bilateral salpingectomy , bilateral oophorectomy orhysterectom y). 
For women of childbearing potential who may  participate in the study , the following methods 
of contraception, if properly
 used, are generall y considered reliable: hormonal contraceptives
(ie, oral, patch, 
vaginal ring, injection ,implant ), male condom with intravaginal spermicide, 
13AUG2018 CSR UBR-MD-01
24

Allergan Confidential Protocol UBR -MD-01 Amendment 3
25diaphragm or cervical cap with spermicide, intrauterine device, vasectomized partner ,or 
sexual abstinence.
For m ales w ho may  participate in the study , the following methods of contraception, if 
properl y used, ar e generally  considered reliable: post-bilateral vasectomy , barrier 
contraception ,or sexual abstinence. Male participants must also refrain f rom donating sperm 
during the course of the study .
The investigator and each patient will determine the appropriate method of contraception for 
the patient during the participation in the study .
If a female becomes pregnant during the stud y, the investigator will notify  Allergan 
immediately after the pregnancy  is confirmed and the patient will be exited from the study
after appropriate safety  follow -up. T he investigator will (1) notify  the patient’s  physician that 
the patient was being treated with investigational drug ubrogepant , and (2) follow the 
progress of the pregnancy . The investigator must document the outcome o f the pregnancy  
and provide a cop y of the documentation to Allergan.
4.5.2 Prohibited Medications/T reatments
The following medications are prohibited 30 day s prior to Visit 1 and throughout the stud y 
period:
Strong and moderate cytochrome P450 3A4 ( CYP3A4 )inhibitors, including but not 
limited to: systemic (oral/ IV) itraconazole, ketoconazole, fluconazole; ery thromy cin, 
clarithrom ycin, telithromycin; diltiazem, verapamil; aprepitant ;cyclosporine ;
nefazodone ;cimetidine ;quinine ;and HIV  protease inhibitors
Strong and moderate CYP3A4 inducers, including but not limited to barbiturates 
(eg,phenobarbital and primidone), systemic (oral/IV) glucocorticoids, nevirapine, 
efavirenz, pioglitazone, carbamazepine, phen ytoin, rifampin, rifabutin, and St. John’ s 
wort
I
nhibitors of the BCRP  (breast cancer resistance protein) transporter (eg, rifampicin)
Drugs with narrow therapeutic margins (eg, digoxin, warfarin)
Examples of prohibited medications in the classes noted above are displayed in Section 12.2.
The decision to administer a prohibited medication/treatment is done with the safet y of the 
study  participant as the primary  consideration. When possible, Allergan should be notified 
before the prohibited medication/treatment is administered.
13AUG2018 CSR UBR-MD-01
25
Allergan Confidential Protocol UBR -MD-01 Amendment 3
264.5.3 Special Diet or Activities
Patients must refrain from consuming grapefruit or grapefruit juice from the time the consent 
form is signed until completion of the study . In addition, p atients will be asked to refrain 
from sleeping and consuming caf feine for at least 2 hours af ter they  take IP.
Alcohol intake should be limited to no more than 3 drinks per day  throughout the study . A 
drink is defined as a 12 -ounce can/bottle of beer , a 4-ounce glass of wine, or 1 ounce of 
liquor .
5. Study Treatments
5.1 Study Treatments and Formulations
Ubrogepant  oral compressed tablets containing 50 mg of 
ubrogepant.
5.2 Control Treatment
Ubrogepant placebo  tablets.
5.3 Methods for Masking/Blinding
All study  treatments will be provided in identical blister cards to maintain masking of the 
study .Tablets of ubrogepant 50 mg and placebo will be identical in appearance.
A modified double -dummy  design will be utilized to maintain the study  blind . All patients 
will be instructed to take 2 tablets to treat their migraine attack regardless of the dose gro up 
to which they  are assigned. The treatments to be used in this study  are 
outlined in Table2.
5.4 Treatment Allocation Ratio 
Patients who meet all of the study  entry  criteria will be randomized and provided with IPto 
treat 1 migraine at tack on an outpatient basis. Patients will be assigned randomly  in a 
1:1:1 ratio to 1 of the following 3 treatment groups: placebo, ubrogepant 50 mg,or
ubrogepant 100 mg. 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
26

Allergan Confidential Protocol UBR -MD-01 Amendment 3
27 
 
 
 
 
 
 
 
 
5.5 Method for Assignment to Treatment 
Groups/Randomization /
Prior to initiation of study  treatment, each patient who provides informed consent willbe 
assigned a patient number that will serve as the patient identification number on all study  
documents.
An automated interactive web response sy stem (IWRS) will be used to manage the 
randomization and treatment assignment. At the time of randomization (V isit2), eligible 
patients will be randomly assigned to 1 of 3treatment arms in a 1:1:
1 ratio to placebo, 
ubrogepant 50 mg, or ubrogepant 100 mg  
Allerg an Biostatistics (randomization programmer) will prepare the randomization codes. 
13AUG2018 CSR UBR-MD-01
27

Allergan Confidential Protocol UBR -MD-01 Amendment 3
28IPwill be labele d with medication kit numbers. The I WRS will provide the site with the 
specific medication kit number(s) for each randomized patient at the time of randomiz ation. 
Sites will dispense IPaccording to the IWRS instructions. Sites will receive the I WRS 
confirmation notif ications for each transaction. All notifications are to be maintained with the 
study  source documents.
5.6 Treatment Regimen and Dosing
5.6.1 Treatment Administration
Table2presents the treatments that will be administered in this study . All patients will be 
instructed to take 2 tablets for their initial dose to treat their migraine attack regardless of the 
dose group to which they are assigned. If taking the optional second dose, patients will also 
beinstructed to take 2 tablets.  
Table2 Treatments Administered for Initial and Optional Second Dose
Drug/DoseRoute of 
AdministrationInvestigational 
Product
Administer ed for 
Initial Dose 
 
Placebo Oral (tablet) 50mg placebo/
50mg placebo
Ubrogepant 50 mg Oral (tablet) Ubrogepant 50mg/
50mg placebo
Ubrogepant 100 mg Oral (tablet) Ubrogepant 50mg/
ubrogepant 50 mg
 
 
 
13AUG2018 CSR UBR-MD-01
28

Allergan Confidential Protocol UBR -MD-01 Amendment 3
29 
 
5.6.3 Optional Second Dose and Rescue Medication
Two hours after initial treatment with IP, patients who did not adequatel y respond may  take a 
blinded optional second dose ,active treatment or placebo ,as assign ed at the Randomization 
Visit(Visit 2 ) or patients’  own rescue medication, or may  elect to take no further medication. 
Inadequate response to the initial dose of IPis defined as meeting 1 of the following:
Continues to have a headache th atis either moderate or severe; OR
After initial pain relief at 2 hours (defined as a headache severit y rating of no pain or 
mild pain), moderate or severe headache returns within 2 to 48 hours after the initial 
dose
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
29

Allergan Confidential Protocol UBR -MD-01 Amendment 3
30 
 
 
5.7 Storage of Investigational Product s/Treatments
IPat the site must be stored at room temperature in a secure ly locked cabinet .Further details 
regarding the storage of the IPare in the Study  Reference Manual.
6. Response Measures and Summary of Data Collection Methods
6.1 Efficacy Measur es
Efficacy  measurement assessments are based on information recorded by the patient in an 
eDiary .
Rating of Headache Severity
Headache severit y will be subjectivel y rated b y the patient at predefined timepoints (predose 
and 0.5, 1, 1.5, 2,
3, 4, 6, 8, 24, and 48 hours after the initial dose ) on a scale from no pain to 
severe pain:
No pain
Mild pain
Moderate pain
Severe pain
Migraine Associated Symptoms
The patient will record whether the following associated s ymptoms were present or absent at 
predefined timepoints ( predose and 0.5, 1, 1.5, 2, 3,4, 6, 8, 24, and 48 hours after the initial 
dose):
Photophobia
Phonophobia
Nausea
Vomiting
13AUG2018 CSR UBR-MD-01
30

Allergan Confidential Protocol UBR -MD-01 Amendment 3
31Use of Rescue Medication
Patients will record in their eDiary  any rescue medication taken within 48 hours after treating 
their migraine attack with IP,in addition documenting the date andtime that the rescue 
medication was taken.
Use of Optional Second Dose and Recurrence of Headache Pain
Patients will record in their eDiary  use of the optional second dose of IPdue to inadequate 
response to their initial dose of IP. Date andtime of the second dose will be reported ,as well 
as pain severit y and absence or presence of migraine -associated s ymptoms at the time the 
second dose is taken and 2 hours after taking the second dose.The incidence of recurrence in 
patients who had pain relief and pain freedom at 2 hours after the initial dose will be 
collected.
 
 
 
 
 
 
 
 
 
  
 
 
13AUG2018 CSR UBR-MD-01
31

Allergan Confidential Protocol UBR -MD-01 Amendment 3
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
32

Allergan Confidential Protocol UBR -MD-01 Amendment 3
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
33

Allergan Confidential Protocol UBR -MD-01 Amendment 3
34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
34

Allergan Confidential Protocol UBR -MD-01 Amendment 3
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
35

Allergan Confidential Protocol UBR -MD-01 Amendment 3
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
36

Allergan Confidential Protocol UBR -MD-01 Amendment 3
37 
 
 
 
 
 
 
 
 
 
 
 
 
6.6 Other Study Supplies
The following will be provided by  Allergan :
All supplies needed for blood and urine sampling (central laboratory anal ysis, urine 
culture/sensitivity )and urine dipstick reagent strips

Shipping materials for shipment of laboratory  samples to central laboratory
All supplies needed for ECG assessment including ECG machine
Electronic diaries (eDiary )
Electronic tablets (eTablet)
13AUG2018 CSR UBR-MD-01
37

Allergan Confidential Protocol UBR -MD-01 Amendment 3
386.7 Summary of Methods of Data Collection
An IWRS will be used to randomize patients and man age IPinventory . Datafor this study  
will be collected using eCRFs via an electronic data capture s ystem, eDiaries, and e Tablets .
Source documents will be used at the sites and may include a patient’ s medical record, 
hospital charts, clinic charts, the investigator ’s patient study  files, as well as the results of 
diagnostic tests such as laboratory tests, ECGs, etc.Centrali zed vendors will be used for the 
analysis of all blood/urine samples and ECG assessments. Additional information on the 
collection and handling of samples is detailed in the respective laboratory  manuals.
Patients will use an eDiary to record details assoc iated with their migraine attack, including, 
but not limited to the date and time of dosing, efficacy  assessments (eg , pain severit y, 
absence or presence of migraine -associated s ymptoms), and other important study
information at designated time points post-dose. Training for the eDiary  will be provided for 
qualified patients during the Random ization V isit (Visit 2). For details regarding eDiary  
instructions to patients, 
see the eDiary  manual.
The C -SSRS will be conducted as a clinical interview at each visit and recorded by  qualified
site staf f via an eTablet .
7. Statistical Pr ocedures
7.1 Analysis Populations
7.1.1 Modified Intent -to-treat Population
The Modified Inten t
-to-treat (mITT) Population will consist of all randomized patients who 
received at least 1 dose o f study  treatment, recorded a baseline migraine headache severity  
measurement, and had at least 1 postdose migraine headache severit y or migraine -associated 
symptom measureme nt at or before the 2 -hour time point.
7.1.2 Safety Population
The Safet y Population will consist of all randomized patients who received at least 1 dose of 
study  treatment.
7.2 Collection and Derivation of Efficacy Assessments
7.2.1 Primary Efficacy Variables
The coprimary  efficacy  parameters for the U nited States areas follows:  
13AUG2018 CSR UBR-MD-01
38
Allergan Confidential Protocol UBR -MD-01 Amendment 3
39Pain freedom (PF) at 2 hours after the initial dose , defined as a reduction in headache 
severit y from moderate/severe at baseline to no pain, at 2hours after the initial dose
Absence of the most bothersome migraine- associated sy mpto m (the most bothersome 
migraine -associat ed symptom will be identified at baseline for each patient) at 2hours 
after the initial dose . 
7.2.2 Secondary Efficacy Variables
The secondary  efficacy  parameters for theUnited States are:
Pain relief ( PR)at 2hours after the initial dose , defined as the reduction of a 
moderate/severe migraine headache to a mild headache or to no headache , at 2 hours 
after the initial dose
Sustained pain relief ( SPR)from 2 to 24hours after the initial dose ,defined as pain 
relief with no administration of either rescue medication or the second dose of IP,and 
with no occurrence thereafter of a moderate/severe headache during the relevant 
number of hours after dosing with the IP
Sustained pain freedom (SPF) from 2 to 
24 hours after the initial dose , defined as pain 
freedom with no administration of either r escue medication or the second dose of IP, 
and with no occurrence thereafter of a mild/moderate/severe headache during the 
relevant number of hours after dosing with the IP
Absence of photophobia at 2hours after the initial dose
Absence of phonophobia at 2hours after the initial dose
Absence of nausea at 2hours after the initial dose
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
39

Allergan Confidential Protocol UBR -MD-01 Amendment 3
40 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
40

Allergan Confidential Protocol UBR -MD-01 Amendment 3
41 
 
 
 
 
 
7.3 Hypothesis and Methods of Analysis
The efficacy anal yses will be based on the mITT  Population. The last -observation -carried -
forward (LOCF) approach will be used to impute missing post treatment values. Baseline for 
efficac y is defined as the last nonmissing ef ficacy  assessment before the initial dose of study  
treatment. All statistical tests will be 2 sided hy pothesis tests performed at the 5% level of 
significance for main ef fects. All conf idence intervals will be 2 -sided 95% confidence 
intervals, unless stated otherwise.
7.3.1 Efficacy Analyses
7.3.1.1 Primary Efficacy Analyses
For each primary  variable, the observed response proportions will be provided by  treatment 
group. Theprimary  efficacy  
variable of pain freed omat 2 hours after the initial dose will be 
analyzed using a logistic regression model with categorical terms for treatment group, 
historical triptan response (triptan responder, triptan insufficient responder, or triptan naïve), 
use of medi cation for migraine prevention (y es/no), and baseline headache severit y 
(moderate or severe). The primary  efficacy  variable of absence of the most bothersome 
symptom at 2 hours after the initial dose will be analy zed using a similar logistic regression 
model with an additional categorical term for the underly ing s ymptom that was identified as 
the most bothersome. 
If the logistic regression model fails to converge due to complete or 
quasi -complete separation, Firth’s penalized likelihood method ( Firth, 1993 ) will be used. 
The logistic regression model will be referred to as the primary  model. 
13AUG2018 CSR UBR-MD-01
41

Allergan Confidential Protocol UBR -MD-01 Amendment 3
42The respective comparisons of the ubrogepant dose sversus placebo, which are the formal 
tests of the efficacy  hypotheses, will be conducted using the appropriate pairwise contrasts 
within the logistic regression model. Treatment comparisons will be based on the model -
derived odds ratios and their associated 95% confidence intervals. Two -sided p -values will 
also be provided. 
, thestudy  will be considered a success if at least 1 ubrogepant dose is 
demonstrated to be superior to placebo on both coprimary  variables after multiplicity  
adjustment. 
 
 
.
7.3.1.2 Secondary Efficacy Analyses 
For each secondary  efficacy  endpoint, the observed response proportions will be analy zed 
using the same methods used to anal yze the primary  efficacy  variables. The respective 
comparisons of the ubrogepant doses v ersusplacebo will be conducted using model -derived 
odds ratios, 95% confidence intervals and p -values from the logistic regression model. 
For 
secondary  efficacy  endpoints o n migraine -associated sy mptoms, baseline presence/absence 
of the sy mptom will be included as an additional covariate for the logistic regression model.
A graphical approach b y Bretz et al (2009 )will be used to control the ov erall ty pe I error rate 
for multiple comparisons across the ubrogepant doses and the primary  and secon dary 
efficacy  endpoints. The coprimary  efficacy  endpoints will serve as the gatekeepers of the 
secondary  endpoints. The secondary  endpoints will be tested in the same order as they  appear 
in the list of secondary  endpoints, except for the 3migraine -associated s ymptoms which will 
be treated at the same level to allow the recy clingof weights among the 3symptom 
endpoints. Recy clingof weights between the 2 doses is also allowed. The details of the 
multiple comparison procedure will be provided in the statistical analy sis plan (SAP).
.
 
 
 
13AUG2018 CSR UBR-MD-01
42

Allergan Confidential Protocol UBR -MD-01 Amendment 3
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
43

Allergan Confidential Protocol UBR -MD-01 Amendment 3
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
44

Allergan Confidential Protocol UBR -MD-01 Amendment 3
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
45

Allergan Confidential Protocol UBR -MD-01 Amendment 3
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
46

Allergan Confidential Protocol UBR -MD-01 Amendment 3
47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
47

Allergan Confidential Protocol UBR -MD-01 Amendment 3
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
48

Allergan Confidential Protocol UBR -MD-01 Amendment 3
49 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
49

Allergan Confidential Protocol UBR -MD-01 Amendment 3
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
13AUG2018 CSR UBR-MD-01
50

Allergan Confidential Protocol UBR -MD-01 Amendment 3
51Table4 Assumed Response Rates a nd Estim ated Power for Primary and Secondary Efficacy 
Endpoints
EndpointAssumed Response 
Rate for PlaceboAssumed Response Rate for 
Ubrogepant GroupsPower After Multiplicity 
Adjustment
PF 2h 10% 24% >99%
Absence of the Most 
Bothersome Symptom 2h26.7% 37.7% 88%
PR 2h 34% 56% 88%
SPR 2 to 24h 19% 38% 88%
SPF 2 to 24h 6.5% 14.5% 83%
Absence of Photophobia 2h 32% 44% 78%
Absence of Phonophobia 2h 43% 57% 81%
Absence of Nausea 2h 59% 70% 71%
; h = hours; PF = pain free dom; PR = pain relief; SPF = sustained pain free dom; SPR = 
sustained pain relief
7.6 Interim Analyses
No interim anal ysis is planned for this study .
8. PatientEntry Procedures
8.1.1 Overview of Entry Procedures
Prospective patient s as defined b y the inclusion and exclusion criteria in Sections 4.3and4.4
will be conside red for entry  into this study .
8.1.2 Informed Consent and PatientPrivacy
The study  will be discussed with the patient and a patient wishing to participate must give 
informed consent prior to any  study -related proc edures or change in treatment. The patient
must also give authorization and other written documentation in accordance with local 
13AUG2018 CSR UBR-MD-01
51

Allergan Confidential Protocol UBR -MD-01 Amendment 3
52privacy  requirements (where applicable) prior to any  study -related procedures or change in 
treatment.
Each patient that provides informed consent will be assigned a patient number that will be 
used on patient documentation throughout the study .
 
 
8.2 Washout Intervals/Run -In
This study  will not include a washout period.
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
52

Allergan Confidential Protocol UBR -MD-01 Amendment 3
53 
 
 
 
 
13AUG2018 CSR UBR-MD-01
53

Allergan Confidential Protocol UBR -MD-01 Amendment 3
54 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
54

Allergan Confidential Protocol UBR -MD-01 Amendment 3
55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
55

Allergan Confidential Protocol UBR -MD-01 Amendment 3
56  
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
56

Allergan Confidential Protocol UBR -MD-01 Amendment 3
57 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
57

Allergan Confidential Protocol UBR -MD-01 Amendment 3
58 
 
 
 
 
 
 
 
 
8.5 Instructions for the Patients
Section 4.5.3 provides diet and activity  instructions for patients enrolled in the study .
Patients will be provided with instructions on the use of the eDiary  to complete when they  
experience a qualify ing migraine .A practice session with a hy pothetical scenario should be 
administered to ensure the patients’ comprehension of the questions and the information to be 
entered . In addition, criteria for a qualify ing migraine to be treated as well as prohibited 
medications should be reviewed with the patients. Patients will be instructed to bring their 
eDiary  at the next clinic visit and return their IP(used and unused).
13AUG2018 CSR UBR-MD-01
58

Allergan Confidential Protocol UBR -MD-01 Amendment 3
59 
8.6 Unscheduled Visits
Additional examinations and laboratory  assessments may  be performed as necessary  to 
ensure the safet y and well -being of the patients during the study  period. Unscheduled visit 
eCRFs should be completed for each unscheduled visit. For all parameters not measured, 
indicate “not done”.
8.7 Compliance with Pr otocol
All assessments will be conducted at the appropriate visits as outlined in Table1, and the
timing of the visits should occur as close as possible to the 
specified day . At each visit, the 
patient will be asked if the patient changed the dose/regimen of any  existing concomit ant 
medications orinitiated the use of an y new concomitant medications since the last visit to 
ensure compliance with the protocol. 
Patients will record the requested information regarding their migraine attack and the IP
taken in the eDiary .IPcomplian ce will be closel y monitored by  counting the number of 
tablets dispensed and returned. Every effort will be made to collect all unused IP.
8.8 Early Discontinuation of Patients
A premature discontinuation will occur when a patient who signed the informed conse nt form 
(ICF
)and has been randomized ceases participation in the study , regardless of circumstances, 
before completion of the study .Patients can be prematurely  discontinued from the study  for 
one of the following reasons :
Adverse event (AE)
Protocol violation
Noncompliance with IP
Withdrawal of consent (a clear reason must be documented)
Lost to follow -up. (Every ef fort must be made to contact the patient; a 
certified/traceable letter must be sent .)
Lack of Qualify ing Event (a qualify ing migraine is not treated within 60 day s from 
Randomization [Visit 2] )
Pregnancy
13AUG2018 CSR UBR-MD-01
59

Allergan Confidential Protocol UBR -MD-01 Amendment 3
60Other reasons
Patient s may  voluntaril y withdraw from the stud y at an y time. Notification of earl y patient
discontinuation from the study  and the reason for discontinuation will be clearl y documented 
on the appropriate eCRF .All randomized patients who prematurely discontinue from the 
study , regardless of cause, should be seen for a final assessment. A final a ssessment will be 
defined as completion of the evaluations scheduled for V isit 3/Earl y Termination  
 
. If the patient discontinue safter IPis 
taken, the patient is also expected to return for theSafety  Follow -up V isit(Visit 4) 4 weeks 
postdose .
8.9 Withdrawal Criteria
Women who become pregnant will be withdrawn from the study  (see Section 4.5.1.2) and 
should refrain from taking IP. The patient should return to the clinic for early  termination
procedures (Visit 3), including the safet y follow -up visit (V isit 4) if IPwas taken. 
Patients who reply  with “y es” to questions 4 or 5 in the suicidal ideation section or “y es” to 
any question in the suicidal behavior section of the C -SSRS at Visit 3  
nd should receive appropriate follow -up a s in routine clinical practice , 
including the safet y follow -up visit (V isit 4) if IPwas taken.
A patient with a condition and/or a situation that, in the investigator's opinion, may  put the 
patient at significant risk, may confound the study  results, or may  interfere significantl y with 
the patient's participation in the study  may be withdrawn from treatment.
 
 
 
 
 
.
8.11 Study Termination
Allergan may stop the study (and/or the stud y site) for an y reason with appropriat e 
notification.
13AUG2018 CSR UBR-MD-01
60

Allergan Confidential Protocol UBR -MD-01 Amendment 3
619. Adverse Events
Adverse events occurring during the stud y will be recorded on an a dverse event eCRF . If 
adverse events occur , the first concern will be the safet y of the stud y participants.
9.1 Definitions
9.1.1 Adverse Event
An adverse event is an y untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product and that does not necessarily have a causal 
relationship wi th this treatment. An adverse event can therefore be an y unfavorable and 
unintended sign (including an abnormal laboratory finding), s ymptom, or disease temporally  
associated with the use of a medicinal (investigational) product, whether or not related to the 
medici nal (investigational) product. In addition, during the screening period, ad verse events 
will be assessed regardless of the administration of a pharmaceutical product.
Note:  Adverse events must be collected once informed consent has been obtained, regardless 
of whether or not the patient has been administered study  drug.
Progress ion of treatment indication including new or worsening of anticipated clinical signs 
or sy mptoms, which are collected as clinical efficacy  variables and assessed as unequivocall y 
associated with the disease progression and /or lack of efficacy , should NOT  be reported as 
adverse events unless the disease progression is greater than anticipated in the natural course 
of the disease.
Adverse events will be assessed, documented, and recorded in the eCRF throughout the study  
(ie, after inform ed consent has been 
obtained). At each visit, the investigator will begin b y 
query ing for adverse events by  asking each patient a general, non -directed question such as 
“How have you been feeling since the last visit?” Directed questioning and examination wil l 
then be done as appropriate. All reported adverse events will be documented on the 
appropriate case report form.
9.1.2 Serious Adverse Event
A serious adverse event is any  adverse event occurring at any  dose that results in any  of the 
following outcomes:  death, a life- threate ning adverse event, inpatient hospitalization or 
prolongation of existing hospitalization, a persistent or significant disability/incapacity , or a 
congenital anomal y/birth defect. Important medical events that may  not result in death, be 
life-threatening, or require hospitalization may  be considered a serious adverse event when, 
based upon appropriate medical judgment, they  may  jeopardize the patient and may  require 
13AUG2018 CSR UBR-MD-01
61
Allergan Confidential Protocol UBR -MD-01 Amendment 3
62medical or surgical intervention to prevent one of the outco mes listed in this definition. ( See 
Section 9.3 for procedures for reporting a serious adverse event.)
Allergan considers all cancer adverse events as serious adverse e vents. In addition, Allergan 
considers an y abortion (spontaneous or nonspontaneous) as a serious adverse event.
Preplanned surgeries or procedures for pre -existing, known medical conditions for which a 
patient requires hospitalization is not reportable as a serious adverse event.
Any preplanned surgery  or procedure should be clearl y documented in the site source 
documents by  the medically  qualified investigator at the time of the patient ’s entry  into the 
study . If it has not been documented at the time of the patient ’s entry  into the study , then it 
should be documented as a serious adverse event and reported to Allergan.
9.1.3 Severity
A clinical determination will be made of the intensity  of an adverse event. The severit y 
assessment for a clinical adverse event must be com pleted using the following definitions as 
guidelines:
Mild Awareness of sign or s ymptom, but easily  tolerated
Moderate Discomfort enough to cause interference with usual activity
Severe Incapacitating with inability  to work or do usual activity
9.1.4 Relationship to Study Drug or Study Pr ocedure
A determination will be made of the relationship (if an y) between an adverse event and the 
study  drug or s tudy procedure, as applicable. A causal relationship is present if a 
determination is made that there is a reaso nable possibility  that the adverse event may  have 
been caused b y the drug or study procedure.
9.2 Procedures for Reporting Adverse Events
Any adverse event must be recorded on the appropriate case report form.
All serious adverse events that are drug- related a nd unexpected (not listed as treatment
-
related in the current investigator's brochure) must be reported to the governing Institutional 
Review Board/Independent Ethics Committee (I RB/IEC) as required by  the I RB/IEC, local 
regulations, and the governing heal th authorities. Any adverse event that is marked 
“ongoing” at the exit visit must be followed -up as appropriate.
13AUG2018 CSR UBR-MD-01
62
Allergan Confidential Protocol UBR -MD-01 Amendment 3
639.3 Procedures for Reporting a Serious Adverse Event
Any serious adverse event occurring during the study  period (beginning with informed 
consent) and for at least 30 days after the last dose of study  drug must be immediately  
reported but no later than 24 hours after learning of a seriou s adverse event. Serious adverse 
events must be reported to Allergan or Agent of Allergan (eg, contract research or ganization 
[CRO ]) and recorded on the serious adverse event form. All patient s with a serious adverse 
event must be followed u p and the outcomes reported. The investigator must supply  Allergan
and the IRB/IEC with any additional requested information (eg, autops y reports and 
discharge summaries).
In the event of a serious adverse event, the investigator must:
1.Notify  Allergan immediately  by fax or email using the serious adverse event form 
(contact details can be found on page 1 of the serious adverse event form); phone 
numbers and relevant Allergan personnel contacts are also on the front page of 
protocol.
2. Obtain and maintain in his/her files all pertinent medical records, information, and 
medical judgments from colleagues who assisted in the treatment and follow -up of 
the patient .
3.Provide Allergan with a complete, written description of the adverse event(s) on the 
serious adverse event form describing the event chronologically , including any  
treatment given (eg, medications administered, procedures perfor med) for the adverse 
event(s). Summarize relevant clinical information about the event:  signs, sy mptoms,
diagnosis, clinical course and relevant c linical laboratory  tests, etc. Include any  
additional or alternative explanation(s) for the causality  which includes a statement as 
to whether the event was or was not related to the use of the investigational drug .
4.Promptly  inform the governing I RB/IEC of the serious adverse event as required by  
the IRB/IEC, local regulations, and the governing health authorities.
9.4 Exposure to Investigat ional Productduring Pregnancy
Study  center personnel must report every  pregnanc y from the time he or she signs the ICF for 
the trial until 30 day safter the last dose of IPon the Pregnancy  Form as soon as possible 
(within 24 hours of learning of the pregnancy to the SAE/P regnancy  fax number ,
even if no AE has occurred. Pregnancies in female partners of male patients must also 
be reported. The pregnancy must be followed to term and the outcome reported by  
13AUG2018 CSR UBR-MD-01
63

Allergan Confidential Protocol UBR -MD-01 Amendment 3
64completing a follow -up Pregnancy Form. If, however , the pregnancy  is associated with a
SAE (eg, if the mother is hos pitalized for hemorrhage), in addition to the Pregnancy  Form, a 
separate SAE Form must be filed as described in Section 9.3with the appropriate serious 
criterion (eg, hospitalization) indicated.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
64

Allergan Confidential Protocol UBR -MD-01 Amendment 3
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
65

Allergan Confidential Protocol UBR -MD-01 Amendment 3
66 
 
 
 
 
 
9.7 Procedures for Unmasking of Investigational Pr oduct
When necessary  for the safet y and proper treatment of the patient , the investigator can 
unmask the patient ’s treatment assignment to determine which treatment has been assigned 
and institu te appropriate follow -up care. When possible, the Allergan Medical Monitor
should be notified prior to unmasking IP. The investigator should inform the Allergan 
Medical Monitor of the unmasking if there is no notification prior to the unmasking.
The treatment assignment for the patient can be determined by designated site personnel 
logging on to 
the IWRS via password protected access. The reason for breaking the code 
must be recorded in the patient’ s source documents.
10. Administrative Items
This protocol is to be conducted in accordance with the applicable Good Clinical Prac tice 
(GCP) regulations and guidelines, eg, the ICH Guideline on GCP.
10.1 Protection of Human Patient
s
10.1.1 Compliance With Informed Consent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations
Written informed consent is to be obtained from each patient prior to any  study -related 
activities or procedures in the study , and/or from the patient 's lega lly authorized 
representative.
10.1.2 Compliance With IRB or IEC Regulations
This study  is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103) 
or applicable IEC regulations. The investigator must obtain approval from a properl y 
constituted I RB/IEC prior to initiating the study  and re -approva l or review at least annually . 
Allergan is to be notified immediately if the responsible I RB/IEC has been d isqualified or if 
13AUG2018 CSR UBR-MD-01
66

Allergan Confidential Protocol UBR -MD-01 Amendment 3
67proceedings leading t o disqualification have begun. Copies of all I RB/IEC correspondence 
with the investigator should be provided to Allergan.
10.1.3 Compliance With Good Clinical Practice
This protocol is to be conducted in accordance with the applicable GCP  regulations and 
guidelines.
10.1.4 Compliance With Electronic Records; Electr onic Signatures 
Regulations (US 21 CFR Part 1 1)
This study  is to be conducted in compliance with the regulations on electronic records and 
electronic signature.
10.2 Changes to the Protocol
The investigator must not implement any  deviation from or changes of the protocol without 
approval b y Allergan and prior review and documented approval/favorable opinion from the 
IRB/IEC of a protocol amendment, except where necessary  to elim inate immediate hazards 
to study  patient s, or when the changes involve only  logistical or administrative aspects of the 
study  (eg, change in monitors, change of telephone numbers).
10.3 PatientConfidentiality
A report of the results of this study  may  be published or sent to the appropriate health 
authorities in any  country  in which the study  drug may  ultimatel y be marketed, but the 
patient ’s name will not be disclosed in these documents. The patient 's name may  be disclosed 
to the sponsor of the study , Allergan, or the governing health authorities or the FDA  if they 
inspect the study  records. Appropriate precautions will be taken to maintain confidentiality  of 
medical records and personal information.
10.3.1 PatientPrivacy
Written authorization and other documentation in accordance with local privacy  requirements 
(where applicable) is to be obtained from each patient prior to enrollment into the study , 
and/or from the patient 's legally  authorized representative in accordance with the applicable 
privacy  requirements (eg, HIPAA).
In accordance with HIP AA requirements, additional purposes of this study  may  include 
publishing of anon ymous patient data from the study .
13AUG2018 CSR UBR-MD-01
67
Allergan Confidential Protocol UBR -MD-01 Amendment 3
6810.4 Documentation
10.4.1 Source Documents
Source documents may  include a patient 's medical records, hospital charts, clinic charts, the 
investigator's patient study  files, the eDiary , as well as the results of diagnostic tests, such as 
laboratory  tests and ECGs . The investigator's cop y of the case report forms serves as part of 
the in vestigator's record of a patient 's study -related data.
The following information should be entered into the patient 's medical record:
Patient ’s name
Patient ’s contact information
The date that the patient entered the stud y, patient number , and 
patient randomization 
(or medication kit) number
The study  title and/or the protocol number of the study  and the name of Allergan
A statement that informed consent was obtained (including the date); a statement that 
written authorization or other local patient privacy required documentation for this 
study  has been obtained (including the date)
Dates of all patient visits
Patient’ s medical history
Information rega rding patient’ s diagnosis of migraine headache
All concurrent medications (list all prescription and nonprescription medications being 
taken at the time of enrollment; at each subsequent visit, changes to the list of 
medications should be recorded)
Occurrence and status of any  adverse events
The date the patient exited the study , and a notation as to whet her the 
patient
completed the study  or reason for discontinuation
The results of laboratory  tests performed b y the site (eg, results of urine pregnancy  
tests)
Key study  variables
Source documentation practices must follow Section 4.0 of I CH E6, Good Clinic al Practice: 
Consolidated Guidance and ALCOA, ie, records must be attributable, l egible, 
contemporaneous, original, and accurate.
13AUG2018 CSR UBR-MD-01
68
Allergan Confidential Protocol UBR -MD-01 Amendment 3
6910.4.2 Electronic Case Report Form Completion
The investigator is responsible for ensuring that data are properly  recorded on each pa tient's 
eCRF and related documents. An investigator who has signed the protocol signature page 
should personally  sign for the case report forms (as indicated in the case report forms) to 
ensure that the observations and findings are recorded on the case re port f orms correctly  and 
completely . The eCRFs are to be submitted to Allergan in a timel y manner at the completion 
of the study , or as otherwise specified b y Allergan and will be maintained in a central data 
repository .
10.4.3 Study Summary
An investigator's sum mary  will be provided to Allergan within a short time after the 
completion of the study ,or as designated b y Allergan. A summary  is also to be provided to 
the responsible IRB/IEC.
10.4.4 Retention of Documentation
All study  related correspondence, patient records , consent forms, patient privacy  
documentation, records of the distribution and use of all investigational products, and copies 
of case report forms should be maintained on file.
For countries falling within the scope of the ICH guidelines, Allergan -specif ic essential 
documents should be retained until at least 2 y ears after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an I CH region or at least 2 y ears have elapsed sin ce the formal 
discontinuation of clinical development of the investigational pro duct. These documents 
should be retained for a longer period, however , if required b y the applicable regulatory 
requirement(s) or if needed by  the sponsor .
In addition, for cou ntries not falling within the scope of the ICH guidelines, local regulatory  
requirements should be followed regarding the retention of clinical study  documentation.
Allergan requires that it be notified in writing if the investigator wishes to relinquish 
ownership of the data so that mutually  agreed -upon arrangements can be made for transfer of 
ownership to a suitably  qualified, responsible person.
13AUG2018 CSR UBR-MD-01
69
Allergan Confidential Protocol UBR -MD-01 Amendment 3
7010.5 Labeling, Pack aging, and Return or Disposal of Investigational 
Products/Treatments
10.5.1 Labeling/Pack aging
IPwill be supplied in blister cards and will be labelled with the protocol number , storage 
information, warning language ,and instructions to take the tablets as directed. The card will 
also include the medication number . Immediately  before dispensing the blister card, the 
investigator or designee will write the study  center number , patient’ s initials and patient
number ,and date on the blister card .
10.5.2 Clinical Supply Inventory
The investigator must keep an accurate accounting of the number of investigational units 
received from Allergan, dispensed or administered to the patient s, the number of units 
returned to the investigator by  the patient (if applicable), and the number of units returned to 
Allergan during and a t the completion of the stud y. A detailed inventory  must be compl eted 
of all used and unused IPand packaging . The IPmust be dispensed or administered only  by 
an appropriatel y qualified person to patient s in the stud y. The medication is to be used in 
accordance with the protocol.
10.5.3 Return or Disposal of Investigational Product s/Treatments 
and/or Supplies
All clinical IPs/treatments and/or supplies will be returned to Allergan or Aller gan designee 
for destruction.
10.6 Monitoring by the Sponsor
A representative of Allergan will monitor the study on a periodic basis. The determination of 
the extent and nature of monitoring will be based on considerations such as the objective, 
purpose, design, complexity , blinding, size, and endpoints of the study .
Authorized representatives of Allergan or reg ulatory  authority  representatives will conduct 
on-site visits to review , audit and copy  study -related documents. These representatives will 
meet with the investigator(s) and appropriate staf f at mutually  convenient times to discuss 
study -related data and q uestions.
13AUG2018 CSR UBR-MD-01
70
Allergan Confidential Protocol UBR -MD-01 Amendment 3
7110.7 Handling of Biological Specimens/Samples
Urine pregnancy  test kits will be provided by  the central lab; all urine pregnancy  testing will 
be administered on site according to instructions in the central lab manual. 
Samples of blood and urine for evaluation of hematology , blood chemist ry, urinaly sis, 
coagulation, serology ,and the urine drug screen will be analy zed at a centralized clinical 
laboratory  with certification from a recognized accreditation agency  (eg, College of 
American Pathology  [CAP] or Clinical L aboratory I mprovement Amendments [CLIA] 
certification).
 
 
 
All samples will be returned to Allergan or Allergan’ s designee for destruction. Allergan shall 
have full ownership rights to any  biological specimens/ samples derived from the study .For 
additional details regarding handling of biological samples please refer to the Laboratory  
Manual .
10.8 Publications
Allergan ,as the sponsor , has proprietary  interest in this study . Authorship and manuscript 
composition will reflect joint cooperation between multiple investigators and sites and 
Allergan personnel. Authorship will be established prior to the wr iting of the manuscript. As 
this study  involves multiple centers, no individual publications will be allowed prior to 
completion of the final report of the multicenter study  except as agreed with Allergan.
10.9 Coordinating Investigator
A signatory  Coordinating I nvestigator will be designated prior to the writing of the Clinical 
Study  Report.
13AUG2018 CSR UBR-MD-01
71

Allergan Confidential Protocol UBR -MD-01 Amendment 3
7211. References
Bretz F , Maurer W, Bran nath W , Posch M. A graphical approach to sequentially  rejective 
multiple test procedures. Stat Med. 2009;28:586 –604.
Cady  RK, McAllister PJ, Spierings ELH, Messina J, Carothers J, Djupesland PG, et al. A
randomized, double -blind, placebo -controlled study  of breath powered nasal delivery  of
sumatriptan powder (AVP -825) in the treatment of acute migraine (The TARGET Study ).
Headache 2015;55:88 -100.
Connor KM,Shapiro RE,Diener HC, Lucas S,Kost J
,FanX,FeiK,Assaid C, Li nes C, Ho
TW. Randomized, controlled trial oftelcagepant for theacute treatment ofmigraine. 
Neurolog y. 2009 Sep 22;73(12):970-977.
Firth D. Bias reduction of maximum likelihood estimates. Biometrika.1993;80:27 –38.
Food and Drug Administration Guidance for Industry . Drug -Induced Liver Injury: 
Premarketing Clinical Evaluation ( UCM174090) July , 2009.
http://www .fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf
Goadsb yPJ, Edvinsson L. The trigeminovascular sy stem and migraine: studies 
characterizing cerebrovascular and neuropeptid e changes seen in humans and cats. Ann 
Neurol. 1993;33(1):48 -56.
Grund y SM, Cleeman J I, Bairey  Merz CN, Brewer Jr HB, Clark L T, Hunninghake DB, 
Pasternak RC, Smith Jr SC, and Stone N J. Implications of recent clinical t
rials for the 
National Cholesterol Edu cation Program Adult T reatment Panel III Guidelines. J Am Coll of 
Cardiology . 2004;44:720 -732.
Hu XH, Markson LE,Lipton RB, Stewart WF,Berger ML. Burden ofmigraine inthe 
United States. Arch Intern Med. 1999;159:813 -818.
International Classification of Headache Disorders, 3rd edition (beta version). Headache 
Classification Committee of the International Headache Societ y (IHS). Cephalalgia. 
2013;33(9):629 –808. http://www.ihs -classification.org/_downloads/mixed/International -
Headache -Classification- III-ICHD-III-
2013 -Beta.pdf
Katsarava Z, Buse DC, Mana ck AN, Lipton RB. Defining the dif ferences between episodic 
migraine and chronic m igraine. Curr Pain Headache Rep . 2012;16(1):86 -92.
13AUG2018 CSR UBR-MD-01
72
Allergan Confidential Protocol UBR -MD-01 Amendment 3
73Lipton RB, Bigal ME, Diamond M, Freitag F , Reed MI , Stewart WF, on behalf of the AMPP  
advisory  group. Migraine prevalence, disease burden, and the need for preventive therapy . 
Neurol. 2007;68(5): 343-
349.
National Cholesterol Education Program Adult T reatment Panel III Guidelines.
NIHPublication No. 01-3670, May  2001. 
http://www .scymed.com/en/smnxdj/edzr/edzr9610.htm
Olesen J,Diene r H-
C, Husstedt IW, Goadsb yPJ,Hall D, Meie r U, et al.Calcitoni n
gene -related peptide receptor antagonist BIBN 4096 BSfortheacute treatment ofmigraine.
NEngl J Med. 2004;350(1 1):1104-1110.
Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby  PJ,et al. Headache 
Classification Committee. New appendix criteria open for a broader concept of chronic 
migraine. Cephalalgia. 2006;26(6):742-746.
Stovner L J, Andree C. Prevalence of headache in Europe: a review for the Eurolight Project. 
J Headache Pain. 2010;11:289 –299. 
http://www .ncbi.nlm.nih.gov/pmc/articles/PMC2917556/pdf/10194_2010_Article_217.pdf 
Accessed 05Apr2016
Tepper SJ, Cady  RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, et al. AVP-825 
breath -powered intranasal delivery  system containing 22 mg sumatriptan powder vs 100 mg 
oral sumatriptan in the acute treatment of migraines (The COMP ASS study ): a comparative 
randomized clinical trial across multiple attacks. Heada che. 2015;55 (5):621-635.
13AUG2018 CSR UBR-MD-01
73
Allergan Confidential Protocol UBR -MD-01 Amendment 3
7412. Attachments
12.1 Examination Pr ocedures, Tests, Equipment, and Techniques
12.1.1 International Classification of Headache Disorders , 3rd Edition, 
Beta Version
13AUG2018 CSR UBR-MD-01
74
Allergan Confidential Protocol UBR -MD-01 Amendment 3
75
13AUG2018 CSR UBR-MD-01
75
Allergan Confidential Protocol UBR -MD-01 Amendment 3
76
13AUG2018 CSR UBR-MD-01
76
Allergan Confidential Protocol UBR -MD-01 Amendment 3
77
13AUG2018 CSR UBR-MD-01
77
Allergan Confidential Protocol UBR -MD-01 Amendment 3
78
13AUG2018 CSR UBR-MD-01
78
Allergan Confidential Protocol UBR -MD-01 Amendment 3
79
13AUG2018 CSR UBR-MD-01
79
Allergan Confidential Protocol UBR -MD-01 Amendment 3
80
13AUG2018 CSR UBR-MD-01
80
Allergan Confidential Protocol UBR -MD-01 Amendment 3
81
13AUG2018 CSR UBR-MD-01
81
Allergan Confidential Protocol UBR -MD-01 Amendment 3
82
13AUG2018 CSR UBR-MD-01
82
Allergan Confidential Protocol UBR -MD-01 Amendment 3
83
13AUG2018 CSR UBR-MD-01
83
Allergan Confidential Protocol UBR -MD-01 Amendment 3
84
13AUG2018 CSR UBR-MD-01
84
Allergan Confidential Protocol UBR -MD-01 Amendment 3
85
13AUG2018 CSR UBR-MD-01
85
Allergan Confidential Protocol UBR -MD-01 Amendment 3
86
13AUG2018 CSR UBR-MD-01
86
Allergan Confidential Protocol UBR -MD-01 Amendment 3
87
13AUG2018 CSR UBR-MD-01
87
Allergan Confidential Protocol UBR -MD-01 Amendment 3
88
13AUG2018 CSR UBR-MD-01
88
Allergan Confidential Protocol UBR -MD-01 Amendment 3
8912.2 Examples of Prohibited Medications
Prohibited Medications
The following medications are prohibited 30 day s prior to S creening and throughout the 
study  period:
Strong/Moderate CYP3A4 Inducers Strong/Moderate CYP3A4 Inhibitors
Antidepressant/ 
AntianxietyBarbiturates 
Amobarbital (Amytal®)
Aprobarbital (Alurate®)
Butalbital (Fiorinal®, 
Fioricet®)
Butabarbital (Busodium®, 
Butisol®)
Mephobarbital (Mebaral®)
Pentobarbital (Nembutal®)
Phenobarbital (Luminal®,
Solfoton®)
Secobarbital (Seconal®)Nefazodone (Serzone®)
Antiseizure Carbamazepine (Atretol®, Carbatrol®, 
Epitol®, Equetro®, Tegretol®)
Oxcarbazepine (Trileptal®)
Phenytoin (Dilantin®, Phenytek®)
Primidone (Myidone®, Mysoline®)
Diabetes Pioglitazone (Actos®)
Troglitazone (Rezulin®, Resulin®)
Antiemetic Aprepitant (Emend®)
Antihypertension Diltiazem (Cardizem®)
Verapamil (Calan®, Calan SR®)
Glucocorticoid
(Systemic)Betam ethasone (Celestone®)
Dexamethasone (Baycadron®, 
DexPak®)
Hydrocortisone (Cortef®)
Methylprednisolone (Medrol®)
Prednisolone (Prelone®)
Prednisone (Deltasone®)
Triamcinolone (Kenalog®)
Antibiotics Rifabutin (Mycobutin®) 
Rifampicin/ Rifampin (Rifadin®, 
Rifater®, Rimactane®) Erythromycin ( Benzamycin®, 
EryTab®)
Clarithromycin (Biaxin®)
Telithromycin (Ketek®)
Antifungal Fluconazole (Diflucan®, Trican®)
Itraconazole (Sporanox®)
Ketoconazole (Nizoral®)
Anti-HIV Efavirenz (Stocrin®,Sustiva®) 
Nevirapine (Viramune®)Indinavir (Crixivan®)
Nelfinavir (Viracept®) 
Ritonavir (Norvir®)
Saquinavir (Fortovase®, Invirase®)
Immunosuppressant Cyclosporine - oral/IV only (Neoral®, 
Sandimmune®)
Other St John’s Wort
Enzalutamide (Xtandi®)
Modafinil (Provigil®)Buprenorphine (Cizol®, Subutex®, 
Suboxone®), Quinine , arm odafinil 
(Nuvigil TM)
13AUG2018 CSR UBR-MD-01
89
Allergan Confidential Protocol UBR -MD-01 Amendment 3
90Drugs with Narrow Therapeutic Margins Warfarin (Coumadin®)
Digoxin (Digitek®, Lanoxin®, Digox®)
Cisapride (Prepulsid®, Propulsid®)
Pimozide (Orap®)
The following medications are allowed during the study ; however , they  areprohibited within 
48 hours prior to taking IP:
Triptan Almotriptan (Axert®)
Eletript an (Relpax®)
Frovatriptan (Frova®)
Naratrip tan(Amerge®)
Rizatrip tan(Maxalt®)
Sumatriptan (Imitre x®) 
Zolmitript an(Zomig®)
Ergot Derivative Dihydroergotamine (DHE 45®, Migranal®)
Ergotamine (Cafergot®, Ergomar®, Wigraine®)
Opioid Tram adol (eg, Ultracet®, Ultram®)
Butorphanol (Stadol®)
Codeine -containing analgesics (eg, Tylenol with Codeine #3®)
Hydrocodone (Zohydro ER™ )/Hydrocodone -containing analgesics 
(eg, Vicodin®)
Oxycodone (Oxycontin®, Roxicodone®)/Oxy codone -containing 
analgesics (eg , Percocet®)
Morphine (MS Contin®)
NSAID Aspirin 
Com bination medicines with NSAID s(eg, Excedrin®)
Diclofenac (Arthrotec®, Cataflam®, Voltaren®)
Ibuprofen (eg, Advil®, Excedrin IB®, Motrin®)
Ketoprofen (eg, Orudis®) 
Naproxen (eg, Aleve®, Naprosyn®)
Analgesic Acetaminophen (eg, Tylenol®or any combination drug Tylenol®)
Antiemetic agent Chlorpromazine (Thorazine®)
Hydroxyzine (Vistaril®)
Metoclopramide (Reglan®)
Ondansetron (Zofran®)
Prochlorperazine (Compazine®)
Prom ethazine (Phenergan®, Mepergan®)
Proton Pu mp Inhibitor Esom eprazole (Nexium®)
Lansoprazole (Prevacid®, Zoton®)
Omeprazole (Losec®, Prilosec®, Zegerid®)
Pantoprazole (Pantoloc®, Pantozol®, Protonix®, Som ac®, Zurcal®)
Rabeprazole (Aciphex®, Pariet®, Rabecid®)
13AUG2018 CSR UBR-MD-01
90
Allergan Confidential Protocol UBR -MD-01 Amendment 3
91The following medications are allowed during the study ; however , they  areprohibited within 
24 hours prior to taking IP:
Antacid Aluminum Carbonate Gel (Basaljel®)
Aluminium Hydroxide (AlternaGEL®, Amphojel®)
Aluminium Hydroxide and magnesium hydroxide (Maalox®, Mylanta®)
Bismuth Subsalicylate (Pepto -bismol®)
Calcium Carbonate (Alcalak®, Quick -Eze®, Rennie®, Rolaids®, Titralac®, 
TUMS®)
Hydrotalcite (Talcid®)
Magaldrate plus Simethicone (Pepsil®)
Magnesium Hydroxide (Phillips' Milk of Magnesia®)
Sodium Bicarbonate (Alka -Seltzer®, Bicarbonate of Soda®)
H2Blocker Famotidine (Pepcid®)
Nizatidine (Axid®)
Ranitidine (Zantac®)
Cimetidine (Tagamet®) 
13AUG2018 CSR UBR-MD-01
91
Allergan Confidential Protocol UBR -MD-01 Amendment 3
9212.3 Glossary of Abbreviations
Term/Abbr eviation Definition
AE adverse event
ALCOA attributable, legible, contemporaneous, original, and a ccurate
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOV A analysis of covariance
AST aspartate aminotransferase
BCRP breast cancer resistance protein
BP blood pressure
C2hr plasma concentration at 2 hours postdose
CAP College of American Pathology
CGRP calcitonin gene -related peptide
CGRP  RA CGRP  receptor antagonist
CHD coronary  heart disease
CLIA Clinical L aboratory  Improvement Amendments
CRO contract research organization
C-SSRS Columbia -Suicide Severity  Rating Scale
CV cardiovascular
CYP3A4 cytochrome P450 3A4
DBS dry blood spot
DSMB Data Safet y Monitoring Board
EC 50 half-maximal ef fective concentration
ECG electrocardiogram
eCRF electronic case report form
eDiary electronic diary
eDISH evaluation of drug- induced serious hepatotoxicity
EMA European Medicines Agency
Emax maximum drug ef fect
eTablet electronic tablet
EU European Union
FDS Functional Disability  Scale
EQ-5D- 5L European Quality  of Life – 5-Dimensional – 5- Level 
FDA US Food and Drug Administration
GCP Good Clinical Practices
HIPAA Health Insurance Portability  and Accountability  Act
HIV Human immunodeficiency virus
ICF informed consent form
ICH International Council on Harmonisation
13AUG2018 CSR UBR-MD-01
92
Allergan Confidential Protocol UBR -MD-01 Amendment 3
93ICHD -3 beta International Classification of Headache Disorders crit eria, 3rd
edition (beta version, 2013)
IEC Independent Ethics Committee
IETD investigator emergency treatment disclosure
IgM immunoglobulin M
INR international normalized ratio (blood -clotting test)
IP investigational product
IRB Institutional Review Board
IV intravenous
IWRS interactive web response sy stem
LOCF last observation carried forward
mITT Modified Intent -to-treat
NCEP National Cholesterol Education Program
NSAID nonsteroidal anti- inflammatory  drug
PCS potentially  clinicall y significa nt
PF pain freedom
PGIC Patient Global I mpression of Change
PR pain relief
QTc QT interval corrected for heart rate
QTcF QT interval corrected for heart rate using the Fridericia formula 
(QTcF = QT/(RR)⅓)
SAE serious adverse event
SAP statistical analy sis plan
SSRI selective serotonin reuptake inhibitors
SNRI serotonin norepinephrine reuptake inhibitors
SPF sustained pain freedom
SPR sustained pain relief
TBL total bilirubin
TEAE treatment -emergent adverse event
ULN upper limit of normal
US United States
VAS visual analogue scale
13AUG2018 CSR UBR-MD-01
93

Allergan Confidential Protocol UBR -MD-01 Amendment 3
9412.4 Protocol Amendment 1 Summary
Title:  A Phase 3, Multicenter , Randomized, Double -blind, Placebo -controlled, Single Attack 
Study  to Evaluate the Ef ficacy , Safety , and Tolerability  of Oral Ubrogepant in the Acute 
Treatment of Migraine
Protocol UBR -MD-01 Amendment 1
Date of Amendment:  09 June 2016
Amendment Summary
This summary  includes changes made to Protocol UBR -MD-01 (29 April 2016). This 
protocol was amended to:  1) revise title page, key responder definitions, health outcomes 
measures, and efficacy variables, and 2) clarify  various study  activities.
Following is a summary  of content -oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes. Minor editorial and document formatting 
revisions have not been summarized.
Section Revision Rationale
Protocol Title Page Revised name of the Authorized 
US Agent from Allergan, Inc. to 
Allergan Sales, LLCThe name of Allergan in the US has 
changed
Added Emergency Telephone 
NumberTo remove need to consult the study 
contacts page
Added “Protocol Amendment 1 
Date” to the title pageTo reflect the approval date of 
Amendment 1
Deleted Name and contact 
information of Allergan study 
personnel andTo reflect change in study contacts 
page
Protocol Summary,  
 
 
 
 
  
 
 
 
 
 
  
13AUG2018 CSR UBR-MD-01
94

Allergan Confidential Protocol UBR -MD-01 Amendment 3
95Section Revision Rationale
 
 
  
  
 
 
Section 3.1, 
Adjudication 
Committee and Drug 
Safety Monitoring 
BoardAdded Drug to title and text for 
DSMB, and added that details of 
the DSMB will be provided in a 
separate CharterClarification
  
 
Section 4.5.1.2, 
Definition of Females 
of (Non-) Childbearing 
Potential and/or 
Acceptable 
Contraceptive MethodsAdded to description of male 
contraception methods:  Male 
participants should also refrain 
from donating sperm during the 
course of the study.To clarify that since male study 
participants should use contraception 
during the study, they should also 
refrain from donating sperm per central 
IRB request
Section 5.3, Methods 
for Masking/BlindingAdded to description of study 
treatments: Tablets of 
ubrogepant 50 mg and placebo 
will be identical in appearance.To clarify that ubrogepant and placebo 
tablets will b e indistinguishable to 
maintain blinding
 
  
  
 
  
  
 
  
 
.
  
 
 
  
 
 
  
 
Section 7.4, Subgroup 
  
   
 
13AUG2018 CSR UBR-MD-01
95

Allergan Confidential Protocol UBR -MD-01 Amendment 3
96Section Revision Rationale
  
 
 
 
 
 
  
 
  
 
 
  
 
  
 
  
 
   
 
13AUG2018 CSR UBR-MD-01
96

Allergan Confidential Protocol UBR -MD-01 Amendment 3
9712.5 Protocol Amendment 2 Summary
Title:  A Phase 3, Multicenter , Randomized, Double -blind, Placebo -controlled, Single Attack 
Study  to Evaluate the Ef ficacy , Safety , and Tolerability  of Oral Ubrogepant in the Acute 
Treatment of Migraine
Protocol UBR -MD-01 Amendment 2
Date of Amendment:  04Nov 2016
Amendment Summary
This summary  includes changes made to Protocol UBR -MD-01 Amendment 1, 
(09June 2016). This protocol was amended to: 1) update health outcomes measures and 
efficac y variables; and 2) clarify  several exclusion criteria 
Following is a summary  of content -oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes. Minor editorial and document formatting 
revisions have not been summarized.
Section Revision Rationale
Global Change Inreference to the Satisfaction With 
Study Medication assessment, in stances 
of“migraine treatment” were changed to 
“study medication ”Based on input from patient 
qualitative interviews, expert panel 
suggested rephrasing “migraine 
treatment” to “study medication ”
Global Change Revised SAE/Pregnancy Reporting Fax 
NumberAdministrative update
Protocol Title Page  Administrative update
Protocol Summary –
General Statistical 
Methods and Types of 
AnalysesRevised to note that PGIC will be 
completed 2 hours after the initial dose : 
…the proportion of patients assessed by 
the PGIC as “much better” or “very 
much better” at 224hours after the 
initial dose will be analyzed using the 
same methods used to analyze the 
primary efficacy variables.Expert input recommended a change 
in PGIC assessment from 24 hours 
to 2 hours after the initial dose to 
increase the probability of 
differentiating between treatment 
and placebo
  
13AUG2018 CSR UBR-MD-01
97

Allergan Confidential Protocol UBR -MD-01 Amendment 3
98Section Revision Rationale
  
 
  
 
 
 
 
 
 
  
Section 3.1, Adjudication 
Committee and Data 
Safety Monitoring BoardSection title and in -text change updated 
to Data Drug Safety Monitoring BoardClarification
Sectio n 4.4 , 
 
 
 
  
 
 
 
 
Section 4.4,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
98

Allergan Confidential Protocol UBR -MD-01 Amendment 3
99Section Revision Rationale
Section 4.4,   
Section 4.4, 
Exclusion 21History of gastric or small intestinal 
surgery (including gastric bypass 
surgery or banding), or has a disease that 
causes malabsorption (eg, Crohn’s 
disease) any prior gastrointestinal (GI) 
conditions (eg, diarrhea syndromes, 
inflammatory bow el disease) that may 
affect the absorption or metabolism of 
investigational product (IP); patients 
with prior gastric bariatric interventions
(eg, Lap Band )which have been
reversed are not excludedClarification on excluded GI 
procedures and conditions including 
inclusion of patients with reversal of 
certain procedures.
Section 4.4,  
 
 
 
 
 
 
 
Section 4.5.1 Permissible 
Medications/TreatmentsDeleted “any proton pump inhibitor” 
from list of medications prohibited 
within 24 hours prior to taking IP and 
added it to list of medications prohibited 
within 48 hours prior to IP dosingAmended per FDA request
Section 4.5.1 .2 
Definition of Females of 
(Non -) Childbearing 
Potential and/or 
Acceptable 
Contraceptive MethodsMoved surgical sterilization from a 
method of contraception to defining 
women of childbearing potential :
For purposes of this study, females will 
be considered of childbearing potential 
unless they are naturally postmenopausal 
(ie, no menses for 2 years) or 
permanently sterilized (ie, bilateral tubal 
ligation ,bilateral salpingectomy, 
bilateral oophorectomy or
hysterectomy).Clarification
13AUG2018 CSR UBR-MD-01
99

Allergan Confidential Protocol UBR -MD-01 Amendment 3
100Section Revision Rationale
Section 4.5.1 .2 
Definition of Females of 
(Non -) Childbearing 
Potential and/or 
Acceptable 
Contraceptive MethodsUpdated acceptable contraceptive 
methods:
For w omen of childbearing potential 
who may participate in the study, the 
following methods of contraception, if 
properly used, are generally considered 
reliable: horm onal contraceptives (ie, 
oral, patch, vaginal ring, injection, 
implant), male condom with intravaginal 
spermicide, diaphragm or cervical cap 
with spermicide, vaginal contraceptive 
ring, intrauterine device, surgical 
sterilization (bilateral tubal ligation, 
bilateral salpingectomy), vasectomized 
partner, or sexual abstinence ….. Male 
participants should must also refrain 
from donating sperm during the course 
of the study .Clarification
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
13AUG2018 CSR UBR-MD-01
100

Allergan Confidential Protocol UBR -MD-01 Amendment 3
101Section Revision Rationale
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
  
 
  
 
 
 
 
  
 
 
 
 
 
  
 
  
13AUG2018 CSR UBR-MD-01
101

Allergan Confidential Protocol UBR -MD-01 Amendment 3
102Section Revision Rationale
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Section 12.2 Examples 
of Prohibited 
MedicationsAdded “(Systemic) ”to Glucocorticoid 
classClarification that only systemic 
glucocorticoids are excluded
Added to “Others” category : arm odafinil 
(NuvigilTM)Clarification
Deleted the following Proton Pump 
Inhibitors from the list of medications 
prohibited w ithin 24 hours prior to IP 
dosing and added them to the list of 
medications prohibited w ithin 48 hours 
prior to IP dosing:
Esom eprazole (Nexium®)
Lansoprazole (Prevacid®, Zoton®)
Omeprazole (Losec®, Prilosec®, 
Zegerid®)
Pantoprazole (Pantoloc®,Pantozol®, 
Protonix®, Som ac®, Zurcal®)
Rabeprazole (Aciphex®, Pariet®, 
Rabecid®)Amended per FDA request
13AUG2018 CSR UBR-MD-01
102

Allergan Confidential Protocol UBR -MD-01 Amendment 3
10312.6 Protocol Amendment 3 Summary
Title:  A Phase 3, Multicenter , Randomized, D ouble -blind, Placebo -controlled Single Attack 
Study  to Evaluate the Ef ficacy , Safety , and Tolerability  of Oral Ubrogepant in the Acute 
Treatment of Migraine
Protocol UBR -MD-01 Amendment 3
Date of Amendment:  19May 2017
Amendment Summary
This summary  includes changes made to Protocol UB R-MD-01 Amendment 2, (04 Nov 
2016). This protocol was amended to: 1) increase sample size from 450 t o 550 patients per 
arm; 
2) revise statistical methods to include an additional categorical term to the logistic 
regression anal ysis for the primary  efficacy  variable of absence of the most bothersome 
symptom at 2 hours after the initial dose; 3) revise statistical methods to include an additional 
categorical term to the logistic regression anal ysis for the secondary  efficacy  endpoints on 
migraine -associated s ymptoms; 4
) reorder the secondary  endpoints , 5)  
 
 6) remove the 35% triptan insuf ficient responder 
requirement .
Following is a summary  of content -oriented changes that were made to each section of the 
protocol, and a brief rationale for these ch anges. Minor editorial and document formatting 
revisions have not been summarized.
Section Revision Rationale
Title Page Replaced Emergency Telephone Number and 
Allergan Medical Monitor Contact Information 
with instructions to refer to Study Contact s
Sheet.Administrative update
Protocol Summary , 
Section 3 Study Design, 
Section 4.1 Number of 
PatientsIncreased number of patients to be randomized 
to approximately 1650 (550 patients per 
treatment arm).Sample size re -estimate based 
on updated assumptions
Section 5.5 Method for 
Assignment to Treatment
Groups/Randomization/   
 
 
Section 7.2.2 Secondary 
Efficacy VariableReordered the secondary efficacy parameters for 
both the US  so that SPF from 2 to 24 
(48) hours is listed third, aft er PR at 2 hours and The re -ordering of the 
secondary efficacy endpoints is 
based on new  assum ptions .The 
13AUG2018 CSR UBR-MD-01
103

Allergan Confidential Protocol UBR -MD-01 Amendment 3
104Section Revision Rationale
SPR from 2 to 24 (48) hours. Removed 
satisfaction with study medication and ability to 
function normally at 2 hours from the secondary 
efficacy parameters. 
 
Protocol Summary ,
Section 7.3.1.1 Primary 
Efficacy AnalysesRevised logistic regression model as follows:
For each primary variable, the observed 
response proportions w ill be provided by 
treatment group. The primary efficacy variable 
of pain freedom at 2 hours after the initial dose 
will be analyzed using a logistic regression 
model with categorical terms for treatment 
group, historical triptan response (triptan 
responder, triptan insufficient responder, or 
triptan naïve), use of medication for migraine 
prevention (yes/no), and baseline headache 
severity (moderate or severe). The primary 
efficacy variable of ab sence of the most 
bothersome symptom at 2 hours after the initial 
dose w ill be analyzed using a similar logistic 
regression model with an additional categorical 
term for the underlying symptom that was 
identified as the most bothersome. The treatment resp onse on the 
most bothersome symptom 
varies according to which 
symptom is identified as the 
most bothersome
Protocol Summary ,
Section 7.3.1.2 Secondary 
Efficacy AnalysesRevised logistic regression model to include:
For secondary efficacy endpoints on migr aine-
associated symptoms, baseline presence/absence 
of the symptom will be included as an additional 
covariate for the logistic regression model.The treatment response on 
migraine -associated symptoms 
is different depending on 
whether the patient had the 
symptom at predose baseline.
  
 
 
 
 
 
 
 
 
 
 
 
  
.
13AUG2018 CSR UBR-MD-01
104

Allergan Confidential Protocol UBR -MD-01 Amendment 3
105Section Revision Rationale
 
 
 
 
 
 
 
 
13AUG2018 CSR UBR-MD-01
105
